POSITIVE RESULTS FROM EVALUATION OF EXO-NET IN PANCREATIC CANCER
EXCELLENT SUBB2M BREAST CANCER TEST DATA
• Griffith University releases additional data on BARD1’s SubB2M technology showing 100% specificity and over 95% sensitivity for detection of all stages of breast cancer
• BARD1 aims to develop and commercialise SubB2M-based blood tests for breast cancer to enable earlier detection, inform treatment decisions and improve women’s health outcomes
OUTSTANDING SUBB2M OVARIAN CANCER TEST DATA
~ Griffith University releases data on BARD1’s SubB2M technology showing 100% specificity and sensitivity for detection of all stages of ovarian cancer
~ Paper presenting this data at the Australia New Zealand Gynaecological Oncology Group (ANZGOG) Conference 2021
Melbourne, Australia, 11 February 2021: BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that Griffith University’s Institute of Glycomics has released data showing that SubB2M can be used to detect all stages of ovarian cancer with 100% specificity and 100% sensitivity.
SubB2M is a protein that binds specifically to a sugar molecule called Neu5Gc which is present on a range of cancers. In humans, Neu5Gc is only found on human tumour cells and tumour-associated molecules, potentially making Neu5Gc a highly specific pan-cancer biomarker. BARD1 holds the exclusive worldwide license for the use of SubB2M to detect any cancer.